BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
- 1 December 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 8 (12), 3341-3349
- https://doi.org/10.1158/1535-7163.mct-09-0499
Abstract
BMS-754807 is a potent and reversible inhibitor of the insulin-like growth factor 1 receptor/insulin receptor family kinases (Ki, in vitro, including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, gastric), and hematopoietic (multiple myeloma and leukemia) tumor cell lines (IC50, 5–365 nmol/L); the compound caused apoptosis in a human rhabdomyosarcoma cell line, Rh41, as shown by an accumulation of the sub-G1 fraction, as well as by an increase in poly ADP ribose polymerase and Caspase 3 cleavage. BMS-754807 is active in vivo in multiple (epithelial, mesenchymal, and hematopoietic) xenograft tumor models with tumor growth inhibition ranging from 53% to 115% and at a minimum effective dose of as low as 6.25 mg/kg dosed orally daily. Combination studies with BMS-754807 have been done on multiple human tumor cell types and showed in vitro synergies (combination index, in vivo, at multiple dose levels, resulted in improved clinical outcome over single agent treatment. These data show that BMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family–targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents. [Mol Cancer Ther 2009;8(12):3341–9]Keywords
Other Versions
This publication has 35 references indexed in Scilit:
- Aurora kinase inhibitors in preclinical and clinical testingExpert Opinion on Investigational Drugs, 2009
- IGF-1 Receptor Inhibitors in Clinical Trials—Early LessonsJournal of Mammary Gland Biology and Neoplasia, 2008
- HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924Molecular Cancer Therapeutics, 2008
- Insulin-like Growth Factor-1 Receptor and ErbB Kinase Inhibitor Combinations Block Proliferation and Induce Apoptosis through Cyclin D1 Reduction and Bax ActivationPublished by Elsevier BV ,2008
- Disrupting insulin-like growth factor signaling as a potential cancer therapyMolecular Cancer Therapeutics, 2007
- The insulin-like growth factor-I receptor as a target for cancer therapyEmerging Therapeutic Targets, 2005
- Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871Clinical Cancer Research, 2005
- Crystal Structure of Aurora-2, an Oncogenic Serine/Threonine KinaseJournal of Biological Chemistry, 2002
- Ligand-binding properties of the two isoforms of the human insulin receptorEndocrinology, 1993
- A generalized two-sample Wilcoxon test for doubly censored dataBiometrika, 1965